Article

Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer

2025-02-17

Abstract excerpt

<h4>Summary</h4> Mismatch repair deficiency (MMRd), either due to inherited or somatic mutation, is prevalent in colorectal cancer (CRC) and other cancers. While anti-PD-1 therapy is utilized in both local and advanced disease, up to 50% of MMRd CRC fail to respond. Using animal and human models of MMRd, we determined that interactions between MHC+ C1Q+ CXCL9+ macrophages and TCF+ BHLHE40+ PRF1+ T cell subsets ar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 524d5832-e31e-58fd-9033-58704096517e
DOI: 10.1101/2025.02.12.637954

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancerDOI 10.1101/2025.02.12.637954Read

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.Semantic proximity Read

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read

Immune escape and resistance to immunotherapy in mismatch repair deficient tumorsSemantic proximity Read

COX-2 regulates IL-17A-producing γδ T cells to drive mismatch repair-deficient colon cancerSemantic proximity Read

Modulating the tumor immune phenotypes by radiotherapy: formulating and validating the combination therapy of radiation, PD-L1, and TIM-3 blockade in colorectal cancer.Semantic proximity Read

Immunotherapy for the treatment of colorectal cancerSemantic proximity Read

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer LandscapeSemantic proximity Read

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsSemantic proximity Read

Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Semantic proximity Read

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver MetastasesSemantic proximity Read

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Semantic proximity Read

Targeting MAFB potentiates immune checkpoint inhibitor efficacy by reprogramming tumor-associated macrophages to an M1-like phenotype in colorectal cancer.Semantic proximity Read